Department of Hematology, Dongyang Hospital Affiliated to WenZhou Medical University, Dongyang People's Hospital, Dongyang, China.
Affiliated Hangzhou First People's Hospital, School of Medicine, WestLake University, Hangzhou, China.
Cell Transplant. 2024 Jan-Dec;33:9636897241293964. doi: 10.1177/09636897241293964.
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary immunotherapy that has shown significant success in treating certain hematologic malignancies. However, there are still challenges and limitations associated with this therapy, and not all cancer patients benefit from this therapy alone. Therefore, modifying CAR-T-cell therapy based on immune checkpoints, and its combination with immune checkpoint inhibitors (ICIs), shows promise as a potentially more effective strategy for treating hematologic malignancies. This article outlines the progress of preclinical and clinical trials of CAR-T-cell therapy based on immune checkpoint modulation in the treatment of hematologic malignancies.
嵌合抗原受体 (CAR) T 细胞疗法是一种革命性的免疫疗法，在治疗某些血液系统恶性肿瘤方面已取得显著成效。然而，该疗法仍然存在挑战和局限性，并非所有癌症患者都能单独从该疗法中受益。因此，基于免疫检查点对 CAR-T 细胞疗法进行修饰，并与免疫检查点抑制剂 (ICI) 联合使用，有望成为治疗血液系统恶性肿瘤的一种更有效的策略。本文概述了基于免疫检查点调节的 CAR-T 细胞疗法在血液系统恶性肿瘤治疗中的临床前和临床试验进展。
